Drugmakers say Japan R&D spending at risk after government forces price cuts

TOKYO (Reuters) - Global drugmakers said they could cut research spending in Japan due to new rules requiring them to slash prices on some blockbuster drugs, including Gilead Sciences Inc's highly effective but expensive hepatitis C drug, Sovaldi.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro